TGF beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: evidence in support of an autocrine hypothesis
- PMID: 8200640
- DOI: 10.1016/0046-8177(94)90118-x
TGF beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: evidence in support of an autocrine hypothesis
Abstract
Our previous investigations of transforming growth factor types beta 1 and beta 2 (TGF beta s) showed negative or positive autocrine growth regulation of gliomas in vitro. Near-diploid gliomas were inhibited by the TGF beta s, whereas a stimulatory response correlated with progressive anaplasia and karyotypic divergence. We have tested the hypothesis that cytogenetic aberrations may be associated with conversion of TGF beta autoregulation from inhibitory to stimulatory among other cultured neuroectodermal tumors. Anchorage-independent growth and karyotypic aberrations supported the malignant nature in vitro of two medulloblastoma (MBL), two primitive neuroectodermal tumor (PNET), and two ependymoma (EPD) cultures. Transforming growth factor type beta 1 and/or TGF beta 2 RNA was evident by Northern blot analysis among these cell cultures. By radioreceptor assay active TGF beta was present in conditioned medium in concentrations of 0 to 14 ng/mL, whereas the total amount of active and latent TGF beta secreted was in the range of 3 to 118 ng/mL. Expression of the TGF beta radioreceptor (TGF beta-R) types I and II was shown by cross-linking assay. Responses to exogenous TGF beta were determined by [3H]-thymidine incorporation, cell counts, and anchorage-independent clonogenicity. Exogenous TGF beta was growth inhibitory for the near-diploid MBL, PNET, and EPD in vitro, as well as antagonistic to the mitogenic effect of epidermal growth factor (EGF) and insulin. In contrast, MBL, PNET, and EPD with a hyperdiploid subpopulation were stimulated to proliferate in monolayer culture or soft agar by TGF beta 1 and TGF beta 2. The growth response did not correlate with TGF beta-R type. Autocrine regulation was supported by antibody neutralization experiments performed with quiescent cells in the absence of exogenous TGF beta. Anti-TGF beta antisera enhanced the growth of TGF beta-inhibited cultures, whereas the TGF beta-stimulated cultures were inhibited by the antisera. Karyotypic divergence seemed to predict response as MBL, PNET, and EPD with hyperdiploid elements exhibited autocrine TGF beta-stimulation. In contrast, the near-diploid cultures were inhibited by the TGF beta s. By analogy with the gliomas, conversion of TGF beta autocrine regulation from inhibition to stimulation may be a late progression marker of anaplasia among MBL, PNET, and EPD. Secretion of this TGF, which serves both as a mitogen and immunosuppressive agent may contribute to the adverse prognosis of hyperdiploid neuroectodermal neoplasms of the central nervous system (CNS).
Similar articles
-
TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis.Int J Cancer. 1991 Aug 19;49(1):129-39. doi: 10.1002/ijc.2910490124. Int J Cancer. 1991. PMID: 1874566
-
Transforming growth factor beta as a potential tumor progression factor among hyperdiploid glioblastoma cultures: evidence for the role of platelet-derived growth factor.J Neurooncol. 1997 Feb;31(3):233-54. doi: 10.1023/a:1005767616500. J Neurooncol. 1997. PMID: 9049853
-
Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta.Cell Growth Differ. 1990 Aug;1(8):367-74. Cell Growth Differ. 1990. PMID: 2177634
-
Transforming growth factor-beta in neural embryogenesis and neoplasia.Hum Pathol. 1993 May;24(5):457-62. doi: 10.1016/0046-8177(93)90156-b. Hum Pathol. 1993. PMID: 8387957 Review.
-
In vivo and in vitro models of medulloblastomas and other primitive neuroectodermal brain tumors of childhood.Mol Chem Neuropathol. 1994 Feb-Apr;21(2-3):219-39. doi: 10.1007/BF02815352. Mol Chem Neuropathol. 1994. PMID: 8086035 Review.
Cited by
-
Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall.Cancer Cell Int. 2012 Sep 20;12(1):41. doi: 10.1186/1475-2867-12-41. Cancer Cell Int. 2012. PMID: 22995409 Free PMC article.
-
Immunosuppression in Medulloblastoma: Insights into Cancer Immunity and Immunotherapy.Curr Treat Options Oncol. 2021 Jul 30;22(9):83. doi: 10.1007/s11864-021-00874-9. Curr Treat Options Oncol. 2021. PMID: 34328587 Review.
-
LOXL1-AS1 contributes to metastasis in sonic-hedgehog medulloblastoma by promoting cancer stem-like phenotypes.J Exp Clin Cancer Res. 2024 Apr 30;43(1):130. doi: 10.1186/s13046-024-03057-0. J Exp Clin Cancer Res. 2024. PMID: 38689348 Free PMC article.
-
Human Patient-Derived Brain Tumor Models to Recapitulate Ependymoma Tumor Vasculature.Bioengineering (Basel). 2023 Jul 15;10(7):840. doi: 10.3390/bioengineering10070840. Bioengineering (Basel). 2023. PMID: 37508868 Free PMC article.
-
A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo.Neuro Oncol. 2010 Jun;12(6):580-94. doi: 10.1093/neuonc/nop056. Epub 2010 Feb 8. Neuro Oncol. 2010. PMID: 20511191 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous